Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.

In people with colorectal liver metastases from GALAXY, ctDNA was measured with a personalized tumor-informed 16-plex PCR sequencing assay and examined against the survival association of adjuvant chemotherapy.

Annals of OncologyPubMed 39293512DOI 10.1016/j.annonc.2024.08.2240